2024-04-162024-04-162024-03-21https://hdl.handle.net/20.500.12503/32593Research Appreciation Day Award Winner - School of Biomedical Sciences, 2024 Department of Microbiology, Immunology & Genetics (Cell Biology, Immunology & Microbiology) Award - 2nd PlaceCholangiocarcinoma, CCA, is an aggressive type of liver cancer due to the scarce number of biomarkers and its resistance to anticancer drugs, leading to difficulty in its early detection. Its 5-year survival rate ranges from 2% to 24%, depending on severity and metastasis. Currently, surgery is the most effective treatment option, but only under certain criteria, such as the cancer being caught early and having not metastasized. CCA incidence is the highest in Asian countries because of the presence of a carcinogenic liver fluke. N-acetyl transferase, NAT, is an enzyme with many functions, including regulating protein stability, membrane targeting, gene silencing, and drug resistance. Different subsets of NATs are also known to be biomarkers for different types of cancer, such as colorectal, prostate, and breast cancers. According to The Cancer Genome Atlas database, NAT9, a subset of the NAT family, is overexpressed in patients with CCA; however, no studies have demonstrated its role in CCA, indicating the need for more research. In this study, we aim to assess the expression of NAT9 in CCA using cell lines and patient tissue samples through RT-qPCR, western blotting, and immunohistochemistry. This data will help us shed light on NAT9’s role in the tumorigenesis of CCA and could be a promising biomarker and therapeutic target for CCA.enposter